and Kallmann syndrome (KS) [3] [4] [5] . To date, several FGFR1 abnormalities have been identified in patients with IHH/KS mostly as monoallelic mutations, although in a certain percentage of patients, they appeared as digenic or biallelic mutations [5] .
It has recently been postulated that IHH, KS, septo-optic dysplasia (SOD), and combined pituitary hormone deficiency (CPHD) are genetically related conditions caused by abnormal development of the anterior commercially available MLPA probe mix (P133 kit; MRC-Holland, Amsterdam, The Netherlands). To confirm a deletion, we performed fluorescence in situ hybridization (FISH) analysis on lymphocyte metaphase spreads using a PCR-generated probe. The extent of a deletion was analyzed by an oligoarray-based comparative genomic hybridization (CGH) using 1×244K human catalog array (G4411B; Agilent Technologies, Palo Alto, CA, USA). The size and location of a deletion were analyzed using the UCSC genome browser (http://genome.ucsc.edu/).
Mutation analysis
Direct sequence analysis was carried out for the coding exons and their flanking splice sites of FGFR1. The primers utilized in this study are shown in Table 1 . To confirm a heterozygous nucleotide substitution, the corresponding PCR products were subcloned using a TOPO TA Cloning Kit (Life Technologies, Carlsbad, CA, USA), and the two alleles were sequenced separately.
Functional analysis of missense variants
For missense variants, in vitro reporter assays were carried out by a previously reported method with modifications [11, 12] . In brief, an expression vector for the wildtype (WT) FGFR1 was constructed by inserting the PCR-amplified cDNA of human FGFR1 into a pcDNA3.1 + vector (Life Technologies). An expression vector for the FGFR1 variants was generated by site-directed mutagenesis. A reporter vector was constructed by inserting the rat osteocalcin promoter sequence (from -206 to +38) into the PGL3-basic luciferase vector (Promega Madison, WI, USA). Transfection assays were carried out using rat L6 myoblast cells (CRL-1458, ATCC) that lacked endogenous Fgfr1 expression. The cells were maintained in DMEM containing 10% fetal bovine serum and seeded into 24-well dishes. Transient transfection was performed using FuGENE 6 Reagent (Roche Diagnostics, Basel, Switzerland) with: (1) empty pcDNA3.1 + expression vector (200 ng), (2) WT FGFR1 expression vector (200 ng), (3) variant FGFR1 expression vector (200 ng), or (4) variant (100 ng) plus WT (100 ng) FGFR1 expression vectors, together with the luciferase reporter plasmids (60 ng) and a pRL-null vector (25 ng, Promega) used as an internal control. At 24 hours after transfection, the medium was replaced by fresh medium supplemented with 2.0 nM FGF8 (Wako, Osaka, Japan), 1.0 μg/mL heparin (Sigma-Aldrich, St. Louis, MO, USA), and 0.1% fetal bovine serum. The midline in the forebrain [6, 7] . Mutations in FGF8, PROKR2, and KAL1 have been identified in patients with IHH, KS, SOD, and/or CPHD [6, 7] . Furthermore, FGFR1 mutations have been detected in a few patients with SOD [7] .
Until now, however, FGFR1 mutations have not been described in patients with CPHD, with the exception of a cytogenetically detectable large deletion involving FGFR1 that was identified in a single case [8] . Therefore, although a positive role of FGF-FGFR signaling in the proliferation of pituitary cells has been indicated by in vitro studies [9, 10] , it remains to be determined whether genetic defects in FGFR1 lead to CPHD. To clarify this, we performed copy-number and mutation analyses of FGFR1 for patients with CPHD.
Patients and Methods

Patients
This study was approved by the Institutional Review Board Committee at the National Center for Child Health and Development and was performed after obtaining written informed consent. We studied 69 Japanese patients (37 males and 32 females aged 1-43 years) with combined deficiencies of at least two pituitary hormones and a normal karyotype. Two of the 69 patients had a family history of pituitary dysfunction. The 69 patients invariably manifested GH deficiency. In addition, most patients had deficiencies of TSH and/or prolactin. Apparent ACTH and ADH deficiencies were observed in 24 and 6 patients, respectively. Of 41 patients examined after the pubertal age of normal children, 32 showed compromised FSH/LH secretion. Brain magnetic resonance imaging delineated pituitary hypoplasia in 34 patients, and stalk interruption in seven. Eleven patients, including four with SOD, exhibited eye abnormalities. Seven patients manifested clinically discernible developmental delay. Patients with a history of birth trauma and those carrying protein-altering mutations or copy-number aberrations of POU1F1, PROP1, HESX1, LHX3, LHX4, OTX2, and SOX3 were excluded from this study. DNA samples of 100 healthy Japanese adults were utilized as controls.
Copy-number analyses
Genomic DNA samples were obtained from leukocytes of the patients. Multiplex ligation-dependent probe amplification (MLPA) was carried out using a CGH revealed that the deletion was ~8.5 Mb in size and included all exons of FGFR1 (Fig. 1B) . In addition to FGFR1, this deletion affected 55 genes and pseudogenes (Table 2 ). Parental samples of the patient were not available for genetic analysis. This deletion was not detected in the control group.
Identification of two FGFR1 missense variants
Direct sequence analysis identified two heterozygous variations, p.V102I (c.304 G>A) and p.S107L (c.320 C>T), in two female patients ( Fig. 2A) . The father of the p.V102I-positive patient also carried this variation, while parental samples of the p.S107L-positive patient were not available for genetic analysis. The p.V102I and p.S107L variants were found in two and one of the 100 control individuals, respectively. cells were cultured for an additional 18 hours and then subjected to luciferase analysis using the luciferase reporter assay system (Promega). Relative luciferase activity was measured with Lumat LB9507 (Berthold, Oak Ridge, TN, USA). These experiments were carried out in triplicate within a single experiment and the experiment was repeated three times. The results are expressed as the mean ± SEM, and statistical significance was determined by the t-tests. Values of p ≤ 0.05 were considered significant.
results
Identification of a submicroscopic deletion involving FGFR1
A heterozygous deletion involving FGFR1 was identified in one female patient. This deletion was indicated by MLPA and confirmed by FISH (Fig. 1A) . 
Functional analysis of missense variants
In vitro functional assays were carried out for the p.V102I and p.S107L variants (Fig. 2B and C) . The relative luciferase activity of p.S107L did not significantly differ from that of WT (p = 0.0552). Furthermore, although p.V102I showed a slightly lower activity compared to WT (p = 0.0413), there was no significant difference in activity between WT and p.V102I plus WT (1:1) (p = 0.0872).
Clinical features of the deletion-positive patient
The deletion-positive patient presented with primary amenorrhea at 20 years of age. She had no family history of pituitary dysfunction; her non-consanguineous parents were clinically normal.
Clinical examinations revealed delayed pubertal development (breast, Tanner stage 3; pubic hair, stage 2-3; axillar hair, stage 1), in addition to short stature (-2.7 SD) and learning disability. She had several episodes of convulsion from eight months of age and was els were normal at the baseline, but did not increase after insulin stimulation. Gonadotropin levels were low at the baseline, and did not respond to GnRH stimulation. Basal and TRH-stimulated values of TSH remained within the reference ranges, while the basal level of free T4 was low. Basal and TRH-stimulated levels of prolactin were normal.
diagnosed as having epilepsy. Brain magnetic resonance imaging delineated Chiari type I malformation and syringomyelia, together with an apparently normal pituitary and stalk (Fig. 3) . She had a normal sense of smell, although we did not perform a quantitative examination of olfactory function. Endocrine evaluation delineated a combined deficiency of pituitary hormones (Table 3 ). Blood GH lev- FGFR1 abnormalities, because the majority of previously reported patients with mutations or deletions of FGFR1 had no hormonal abnormalities with the exception of gonadotropin deficiency [3, 13] . These results can be explained by assuming that during development, GnRH neurons are more vulnerable to FGFR1 abnormalities than the other parts of the anterior midline in the forebrain. Furthermore, the high frequency of gonadotropin deficiency and the rarity of other pituitary hormone deficiencies in patients with FGFR1 abnormalities are consistent with the results of in vitro assays; Norlin et al. have suggested that in the developing pituitary, FGFs play a particularly important role in the specification of the POU1F1-independent progenitor cells including gonadotrophs [9] . The deletion-positive patient manifested a combined deficiency of GH, LH and FSH. In addition, normal TSH values along with a low free T4 level are indicative of central hypothyroidism [14] . Since endocrine evaluation of this patient was fragmentary, it remains unknown whether the primary lesion of her hormonal defects resides in the hypothalamus or in the pituitary. Further studies, such as GHRH stimulation tests or GnRH stimulation tests after GnRH priming, will clarify the origin of CPHD in patients with FGFR1 abnormalities.
Mutation analysis identified two heterozygous FGFR1 variations (p.V102I and p.S107L) in two of 69 patients with CPHD. In vitro assays indicated that heterozygosity of the p.V102I and p.S107L vari-
Discussion
Copy-number analyses identified a submicroscopic deletion involving FGFR1 in one of 69 patients with CPHD. The phenotype of the deletion-positive patient, such as brain anomalies and CPHD, is likely be associated with FGFR1 haploinsufficiency, because none of 55 other genes involved in the deletion are known to play a role in the brain development (NCBI database, http://www.ncbi.nlm.nih.gov/; UCSC Genome Browser, http://genome.ucsc.edu/). However, we could not exclude the possibility that this deletion is a nonpathogenic variant, because parental samples of the patient were not available for genetic analysis. In this regard, it is worth mentioning that previous studies have shown that FGFR1 is clearly expressed throughout the neuroepithelium of the developing brain including Rathke's pouch [6] , and FGF signaling regulates the proliferation and differentiation of cultured pituitary progenitor cells [9, 10] . In addition, the CPHD phenotype has also been described in a patient with a large interstitial deletion on 8p11.2 affecting FGFR1 [8] . These results, in conjunction with previous findings that FGFR1 mutations and deletions are present in a certain part of patients with IHH, KS, and SOD [3, 7] , suggest that FGFR1 abnormalities can be associated with various developmental defects of the anterior midline in the forebrain. Nevertheless, CPHD seems to be a rare manifestation among patients with b GH was measured using the recombinant GH standard, and the peak GH value of 6.0 ng/mL are used as the cutoff value for GH deficiency. c Sufficient hypoglycemic stimulations were obtained during all the insulin provocation tests.
